Syros Pharmaceuticals

Update in progress

SYRS (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for hematologic malignancies. Its lead candidates include Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III for genomically defined myelodysplastic syndrome subsets and Phase II for acute myeloid leukemia; SY-2101, an oral arsenic trioxide for acute promyelocytic leukemia; and SY-5609, a CDK7 inhibitor in Phase I for advanced solid tumors. Formerly LS22, Inc., it was renamed in 2012, was incorporated in 2011, and is headquartered in Cambridge, Massachusetts.

Company score

Sentiment: -0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.09; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive